Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas Alk+ Therapy: A Case Report

Version 1 : Received: 13 January 2021 / Approved: 13 January 2021 / Online: 13 January 2021 (12:58:38 CET)

How to cite: Sica, A.; Sagnelli, C.; Casale, B.; Svaneta, G.; Creta, M.; Calogero, A.; Franco, R.; Sagnelli, E.; Ronchi, A. How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas Alk+ Therapy: A Case Report. Preprints 2021, 2021010249 (doi: 10.20944/preprints202101.0249.v1). Sica, A.; Sagnelli, C.; Casale, B.; Svaneta, G.; Creta, M.; Calogero, A.; Franco, R.; Sagnelli, E.; Ronchi, A. How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas Alk+ Therapy: A Case Report. Preprints 2021, 2021010249 (doi: 10.20944/preprints202101.0249.v1).

Abstract

Background: The t (2; 5) chromosomal rearrangement and resulting nucleophosmin (NPM1) -ALK fusion was first observed in 1994 in anaplastic large cell lymphoma (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab-vedotin. These treatments are regarded as a bridge to allogeneic hematopoietic stem cell transplantation (allo-SCT). Nowadays, transplant procedures and monitoring of chemotherapy patients proceed very slowly because the SARS-CoV-2 pandemic has heavily clogged the hospitals in all countries. Results: A 40-year-old Caucasian woman was first seen at our clinical center in June 2020. She had ALCL ALK +, a history of failure to two previous therapeutic lines and was in complete remission after 12 courses of Brentuximab, still pending allo-SCT after two failed donor selection. Facing of a new therapeutic failure, we requested the Italian drug regulatory agency, and obtained the authorization, to administer 250 mg twice a day of Crizotinib, a drug incomprehensibly not registered for ALCL ALK +. Conclusions: The response to Crizotinib was optimal, since no adverse event occurred, and CT-PET persisted negative; this drug has proved to be a valid bridge to allo-SCT

Subject Areas

Crizotinib; Anaplastic Large Cell Lymphomas ALK+; bridge therapy in NHL ALK+; ALK+ patients; anticancer therapy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.